Ketamine

What Happened: According to the Multidisciplinary Association of Psychedelic Studies (MAPS), a non-profit organization, the FDA is close to greenlighting MDMA as a treatment for PTSD. MAPS reported positive results from a phase-3 trial testing the efficacy of MDMA-assisted...

The first study visit to measure the psychedelic effects of ketamine in the cerebral cortex blood flow is underway,  announced Cybin Inc. (NYSE: CYBN), which is sponsoring the research that will make heavy use of Kernel Flow, a quantitative neuroimaging technology. Without...

PharmaTher, a Toronto-based biotechnology company focused on discovering and developing drugs using Ketamine, received an Orphan Drug Designation (ODD) for a ketamine-based medicine to treat a rare seizure condition.  Status Epilepticus is characterized by a seizure lasting more than five...

PharmaTher Holdings Ltd (OTCQB: PHRRF) (CSE: PHRM), is a Canadian company focused on the development and commercialization of medicines derived from ketamine. PharmaTher announced on Wednesday that the U.S. Food and Drug Administration (FDA) has accepted an application to proceed with a Phase 2...

Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin America's first network of...

In an effort to recognize that not all drug use or possession ought to be punishable by harsh prison sentences, the United Arab Emirates (UAE) is creating amendments to longstanding laws that will stress treatment over jail time for first-time convicts of personal use and possession. Situated...

Psychedelic therapy company, Cybin Inc. (NEO: CYBN) (NYSE: CYBN), recently announced it was awarded a grant for the first psychedelic treatment clinic at New York City’s Lenox Hill Hospital with which it will provide care to marginalized and underserved communities on Manhattan...

In the quest to design effective and affordable psychedelic treatments for a range of maladies that include PTSD and depression, one key thought on the minds of company executives and clinicians alike seems to be how to motivate healthcare insurance companies to cover the cost of psychedelic...

The Australian state of Victoria faces a seminal lawsuit that seeks to make MDMA available for severe mental illness. Attempting to secure permission to treat a gravely ill patient using MDMA (universally known as the street drug ecstasy), psychiatrist Dr. Eli Kotler initiated legal...

Cybin Inc. (NEO: CYBN) (NYSE: CYBN), a biotechnology company focused on progressing psychedelic therapeutics, announced Wednesday that the U.S. Food and Drug Administration (FDA) has authorized an Investigational New Drug application to proceed with the company’s sponsored feasibility study...

Pasithea Therapeutics Corp's (NASDAQ: KTTA) wholly-owned subsidiary, Pasithea Clinics, has administered intravenous (IV) ketamine therapy to its first patients with treatment-resistant depression. Pasithea Clinics commenced IV ketamine infusion therapy in Knightsbridge, London. In sub-...

Part A results from the trial of Seelos Therapeutics Inc’s (NASDAQ: SEEL) intranasal ketamine product candidate, SLS-002, and the clarity around the timing of the Part B data release call for a change in recommendation, according to Roth Capital. The Seelos Therapeutics Analyst: Jonathan...

Johnson & Johnson (NYSE: JNJ) received encouraging news after a FDA panel decision went its way with respect to its treatment-resistant depression drug. Panel Finds Risk-Benefit Favorable A joint committee of the FDA's Psychopharmacologic Drug Advisory Committee and Drug Safety and Risk...